New injection for autoimmune diseases that haven't responded to treatment
Part of Immune system & allergy clinical trials.
This trial tests an experimental injection (called WGb-0301) to see if it can help people with autoimmune diseases like lupus or scleroderma that have not improved with usual treatments. The goal is to find a new option for those who have run out of standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have an autoimmune disease (like lupus, autoimmune hepatitis, inflammatory myopathy, or scleroderma) that has come back or hasn't responded to standard treatment.
- You must be in generally good health, able to care for yourself (KPS score > 60), and have a life expectancy of more than 6 months.
- You must agree to use reliable birth control during the trial and for 30 days after stopping the medication.
- You cannot be allergic to mRNA vaccines or similar products.
- You cannot have active infections, severe heart problems, or uncontrolled other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial is testing an experimental injection called JY231 for people with certain autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. The aim is to see if this treatment can reduce disease activity and improve symptoms.
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
This trial tests a new type of medicine (ABO2203) that trains your immune system to attack the cells causing your autoimmune disease. It's for people who haven't gotten better with standard treatments.
This trial tests an experimental treatment called JY231 for people with certain autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, dermatomyositis, or vasculitis that haven't improved with standard treatments. The goal is to see if JY231 can help control the disease when other options haven't worked.
This study tests an investigational drug called KSVCBD for people with certain autoimmune diseases that haven't improved with standard treatments. It aims to see if the drug is safe and if it can help reduce symptoms.
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.